Intelligencia AI

Intelligencia AI

Enterprise AI that scores a drug's odds of approval

Officially listed
English
Paid
AI药物研发
0favorites
0views
Promote this tool
Intelligencia AI screenshot

Tool details

A drug takes more than a decade to travel from phase one to market, and most failures only surface after phase two. Intelligencia AI turns that into a probability question: it scores an asset's PTRS first, then tells you which factors pushed the number up or pulled it down.

Core capabilities

  • PTRS prediction: gives the odds an asset clears its technical and regulatory hurdles and wins approval, with sensitivity analysis on trial design parameters.
  • Competitor and pipeline tracking: follows rival programmes by phase, arm and endpoint so you can see how crowded the field is.
  • Dynamic benchmarks: industry transition rates by indication and phase, replacing the historical range your team used to guess at.
  • Explainability: lays out the features driving a prediction so you can answer why the score is what it is instead of trusting a black box.
  • Data subscription: the curated dataset underneath can be exported wholesale and plugged into your own models.

Where it fits Pipeline planning at pharma companies, business development and licensing diligence, clinical trial design, and banks or hedge funds assessing assets under development. A typical day looks like this: someone in a portfolio review asks whether an asset deserves phase three funding, and you bring the score, the benchmark for that indication and the specific factors dragging it down. Customers are mid-size to large pharma, CROs and consultancies; there is no self-serve signup, so individuals and small teams are effectively locked out.

What sets it apart The data is curated by a biomedical team and ingested daily, the method carries a US patent, and the product insists on explainability rather than a mysterious score. Compared with internal expert elicitation, it at least offers a reproducible yardstick you can benchmark against.

Editorial take The company claims 80% prospective and 91% retrospective accuracy as of early 2024, but the evaluation method is unpublished and unaudited, so demand a live validation before buying. Pricing is quote-only with no free tier and a long procurement cycle; for teams without deep clinical data, the real value is the external benchmark rather than the prediction itself.

Pricing

Custom pricingQuote only (demo required)
Portfolio Optimizer
Quoted per scope

Core SaaS with PTRS prediction, competitor tracking and explainability, priced by assets and seats

Data subscription (DaaS)
Quoted per scope

Wholesale export of the curated dataset for in-house models, priced by coverage and refresh cadence

Additional notes

No pricing page and no self-serve signup; every engagement starts with a demo request. Customers are mid-size to large pharma, CROs, consultancies and financial buyers.

FAQ

It is a New York AI drug development company founded in 2017 that uses machine learning to estimate PTRS, the probability an asset clears technical and regulatory hurdles, through Portfolio Optimizer, Dynamic Benchmarks and a data subscription.

User reviews

User Reviews

No reviews yet

No one has reviewed this tool yet